Clinical research
Novartis, a leader reimagining rheumatology and immunodermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with nr-axSpA (non-radiographic axial spondyloarthritis).
Nordic Nanovector ASA (OSE: NANO) will host an R&D day in Oslo.
Acceleron Pharma said the Phase II FSHD trial assessing the efficacy of ACE-083 did not achieve functional secondary endpoints during the study.
Days after the Cambridge-based company halted its BACE inhibitor program for Alzheimer’s disease, the company stopped another clinical trial in idiopathic pulmonary fibrosis due to safety reasons.
The trial is still ongoing, but met its primary endpoint of ASAS40.
BioCardia announced that the independent Data Safety Monitoring Board has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety follow-up results on 35 patients and all additional data available on the 50 patients randomized in the trial as of August 31, 2019.
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., presented data from the Phase 1 clinical trial of AKCEA-TTR-LRx in a poster presentation at the Heart Failure Society of America 23rd Annual Scientific Meeting in Philadelphia, Pennsylvania.
Celgene announced topline data from its Phase III QUAZAR AML-001 trial.
NOXXON Pharma N.V. announced the start of recruitment of newly diagnosed brain cancer patients in a Phase 1/2 clinical trial combining the CXCL12 inhibitor NOX-A12 with radiotherapy.
Orion Biotechnology to Initiate Clinical Trials of Its Innovative Microbicide Gel for HIV Prevention
Orion Biotechnology Canada Ltd. announced that the Polish National Regulatory Agency and Local Ethics Committee have given approval for the OB-002H-101 Phase 1 safety and acceptability study of OB-002H gel to start screening and enrollment.
PRESS RELEASES